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Abstract
Understanding the functional consequences of genetic variation, and how it affects complex 
human disease and quantitative traits, remains a critical challenge for biomedicine. We present an 
analysis of RNA sequencing data from 1641 samples across 43 tissues from 175 individuals, 
generated as part of the pilot phase of the Genotype-Tissue Expression (GTEx) project. We 
describe the landscape of gene expression across tissues, catalog thousands of tissue-specific and 
shared regulatory expression quantitative trait loci (eQTL) variants, describe complex network 
relationships, and identify signals from genome-wide association studies explained by eQTLs. 
These findings provide a systematic understanding of the cellular and biological consequences of 
human genetic variation and of the heterogeneity of such effects among a diverse set of human 
tissues.
Over the past decade, there has been a marked increase in our understanding of the role of 
genetic variation in complex traits and human disease, especially via genome-wide 
association studies (GWAS) that have cataloged thousands of common genetic variants 
affecting human diseases and other traits (1–3). However, the molecular mechanisms by 
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which this genetic variation predisposes individuals to disease are still poorly characterized, 
impeding the development of therapeutic interventions.
The majority of GWAS variants are noncoding, likely manifesting their effects via the 
regulation of gene expression (4, 5). Thus, characterization of the regulatory architecture of 
the human genome is essential, not only for understanding basic biology but also for 
interpreting GWAS loci. Expression quantitative trait locus (eQTL) analysis (6–8) is the 
most common approach used to dissect the effects of genetic variation on gene expression. 
However, comprehensive eQTL data from a range of human tissues are lacking, and eQTL 
databases are biased toward the most accessible tissues. Additionally, although many 
regulatory regions act in a tissue-specific manner (9, 10), it is unknown whether genetic 
variants in regulatory regions have tissue-specific effects as well. Complex diseases are 
often caused by the dysfunction of multiple tissues or cell types, such as pancreatic islets, 
adipose, and skeletal muscle for type 2 diabetes (11, 12), so it is not obvious a priori what 
the causal tissue(s) are for any given GWAS locus or disease. Hence, understanding the role 
of regulatory variants, and the tissues in which they act, is essential for the functional 
interpretation of GWAS loci and insights into disease etiology. The Genotype-Tissue 
Expression (GTEx) Project was designed to address this limitation by establishing a sample 
and data resource to enable studies of the relationship among genetic variation, gene 
expression, and other molecular phenotypes in multiple human tissues (13). To facilitate the 
collection of multiple different tissues per donor, the project obtains recently deceased 
donors through consented next-of-kin donation, from organ donation and rapid autopsy 
settings. The results described here were generated during the project’s pilot phase, prior to 
scaling up collection to 900 donors. All project data are made available at regular intervals 
to qualified researchers through dbGaP. Summary data are available on the GTEx Portal 
(http://gtexportal.org).
Study design
During the pilot, we recruited 237 postmortem donors, collecting an average of 28 tissue 
samples per donor spanning 54 distinct body sites (fig. S1 and tables S1 and S2). Blood-
derived DNA samples were genotyped at approximately 4.3 million sites, with additional 
variants imputed using the 1000 Genomes phase I, resulting in ~6.8 million single-
nucleotide polymorphisms (SNPs) with minor allele frequency (MAF) of ≥5% after quality 
control (tables S3 to S5) (14).
RNA was extracted from all tissues, but quality varied widely, with tissue site and sample 
specific ischemic time accounting for ~40% of the variance in RNA quality (fig. S2). To 
maximize statistical power, we prioritized RNA sequencing of samples from nine tissues 
that were most frequently collected and that routinely met minimum RNA quality criteria: 
adipose (subcutaneous), tibial artery, heart (left ventricle), lung, muscle (skeletal), tibial 
nerve, skin (Sun-exposed), thyroid, and whole blood (Table 1) (14).
We performed 76–base pair (bp) paired-end mRNA sequencing on a total of 1749 samples, 
of which 1641 samples from 43 sites, and 175 donors, constituted our final “pilot data 
freeze” reported on here (14). Median sequencing depth was 82.1 million mapped reads per 
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sample (fig. S3A). The final data freeze included samples from 43 body sites: 29 solid-organ 
tissues, 11 brain sub-regions (with two duplicated regions), a whole-blood sample, and two 
cell lines derived from donor blood [EBV-transformed lymphoblastoid cell lines (LCLs)] 
and skin samples (cultured fibroblasts) (Table 1 and tables S1 and S2). Median sample size 
for the nine high-priority tissues was 105; median sample size for the other 34 sampled sites 
was 18.5.
Gene expression across tissues
We examined the patterns of expression of 53,934 transcribed genes across tissues [on the 
basis of Gencode V12 annotations] (14, 15). The number of biotypes [protein-coding genes, 
pseudogenes, and long noncoding RNAs (lncRNAs)] that were transcribed above a minimal 
threshold [reads per kilobase per million mapped reads (RPKM) > 0.1] was similar for most 
tissues (average of 20,940) (fig. S3B). Testis was an outlier, with substantially more 
transcribed regions detected than other tissues (31,240 on average), many of which are 
lncRNAs. Whole blood was also an outlier, exhibiting the fewest detected transcribed 
regions (17,160 on average).
Hierarchical clustering demonstrated that expression profiles accurately recapitulate tissue 
type, with blood samples forming the primary outgroup (Fig. 1A). The multiple brain 
regions cluster strongly together as a single unit, but among those the 11 individual sub-
sampled regions are less distinct (Fig. 1A and fig. S4A). The most distinct brain region is the 
cerebellum (fig. S4A) (16), with preservation method having little impact on that signal (fig. 
S4B). The distribution of gene expression across tissues is described by Melé et al. (17), 
who show that tissue-specific transcription is typically dominated by a few genes that vary 
from tissue to tissue.
We quantified splicing events (splice junctions, exons, transcripts) by estimating exon 
inclusion levels, measured as PSI (percent spliced in) scores (14, 18). Clustering samples by 
PSI scores also largely, although less clearly, recapitulates tissue type. Samples from the 
brain, not blood, form the primary outgroup (Fig. 1B), which is divided into two groups: A 
group of 227 samples (from the cerebellum and cortex) forms an independent subcluster 
(cluster 1), and a smaller group of 97 samples (cluster 2, dominated by the remaining 
subregions) clusters closer to samples from the rest of the tissues. This is consistent with 
isoform regulation playing a comparatively larger role in defining cellular specificity in the 
brain (18, 19). These analyses are extended in Melé et al. (17) to define tissue-specific 
splicing signatures and to investigate in depth the role of individual variation in splicing.
eQTL analyses: Single-tissue eQTL analysis
A primary goal of the GTEx project is to identify eQTLs for all genes for a range of human 
tissues. Past studies, hampered by the difficulties of obtaining human tissue samples, have 
typically examined no more than three tissues (8, 20). Although our pilot sample sizes are 
modest for eQTL discovery, the breadth of tissues provides an opportunity to assess 
differential eQTL discovery among tissues. Because of our small sample sizes, we primarily 
examined eQTLs that act in cis to the gene (cis-eQTLs; see box S1), as the expected effect 
size of trans-eQTLs (box S1) is too low to be efficiently detected at this time. We calculated 
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cis-eQTLs separately for each of the nine tissues with sufficient sample sizes (>80 donors) 
for all SNPs within ±1 Mb of the transcriptional start site (TSS) of each gene (14). 
Significance correlations between genotypes and gene expression levels were determined by 
linear regression on quantile normalized gene-level expression values, after correction for 
known and inferred technical covariates (fig. S8) (14), using Matrix eQTL (21). To obtain 
gene-specific significance levels while correcting for testing multiple SNPs per gene, we 
computed permutation-adjusted P values for each gene for the most significant SNP per 
gene (14). We defined “eGenes” as genes with at least one SNP in cis significantly 
associated, at a false discovery rate (FDR) of ≤0.05, with expression differences of that gene 
(box S1) (14). A list of the significant SNP-gene pairs detected per eGene can be found on 
the GTEx Portal (http://gtexportal.org).
The number of eGenes ranged from 919 in heart to 2244 in thyroid, with a total of 6486 
unique eGenes across the nine tissues (Fig. 2A). Rerunning the analysis on successively 
downsampled donor subsets from each tissue showed an approximately linear relationship 
between eGenes and sample size (slope of ~21 eGenes per sample; Fig. 2A). Interestingly, 
thyroid and nerve share a steeper slope with ~29 significant eGenes per sample, whereas 
muscle and blood share a shallower trajectory with ~15 eGenes per sample, which may 
reflect the lower transcript complexity observed for these two tissues (17). The number of 
eGenes identified showed no signs of plateauing at current sample sizes in any of the tissues.
Consistent with previous work (20, 22), the majority of the significant cis-eQTLs clustered 
around the TSS of target genes in all nine tissues (fig. S9, A and B, and fig. S10). The eQTL 
signals also tended to show an upstream bias (fig. S10 and tables S6 and S7); an average of 
~80% of significant eQTLs fell within ±100 kb around the TSS, and ~60% of all eQTLs 
were upstream despite testing a similar fraction of SNPs upstream and downstream of the 
TSS (tables S6 and S7) (23). A slight but distinct overrepresentation of nonsignificant 
eQTLs around the TSS (relative to other SNPs near the gene; red versus black line in figs. 
S9A and S11A) supports the existence of additional eGenes, which did not meet 
significance with current sample sizes.
To investigate the sensitivity and validity of our study, in particular because we used tissues 
from deceased donors, we compared the GTEx blood eQTLs to a previously reported eQTL 
study of whole blood samples in ~5300 individuals (7). Although many experimental and 
processing differences exist between these studies, a considerable fraction of GTEx eGenes 
(68%) were replicated in this study at FDR < 5% (14). Given the incomplete overlap in 
variants tested, we also compared our eQTLs against a smaller study of 911 blood samples 
taken from the Estonian Biobank, where we were able to apply a similar eQTL analysis 
pipeline to that used in GTEx and hence get better SNP coverage (fig. S11) (14). Notably, 
98% of GTEx blood eQTLs at FDR < 5% showed consistent allelic direction with those 
eQTLs (P < 10−200, binomial test) (14).
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Multitissue joint discovery of eQTLs: Tissue specificity and sharing of 
eQTLs
The specificity or sharing of eQTLs among different tissues and cell types is of considerable 
biological interest (8, 22, 24), yielding insights into differential genetic regulation among 
tissues. Furthermore, cross-referencing tissue-specific eQTLs with disease genetic 
associations could help identify tissues most relevant to disease biology. We used the GTEx 
pilot data to examine eQTL sharing across multiple tissues and leveraged the large tissue 
range to discover weak but constitutively active eQTLs.
We investigated patterns of eQTL sharing using 22,286 genes (with RPKM > 0.1 in at least 
10 samples) for each of the nine tissues with both a simple non–model-based analysis of 
every pair of tissues (22) and more sophisticated Bayesian models for joint analysis of all 
nine tissues (24, 25). Analyses focused on a ±100-kb window surrounding the TSS for each 
gene, which is smaller than used for the single-tissue analysis, as this is where we observe 
the highest eQTL density.
The non–model-based pairwise analysis method identifies significant SNP-gene pairs in a 
first tissue, and then uses the distribution of the P values for these pairs in the second tissue 
to estimate π1, the proportion of non-null associations in the second tissue (22, 26). 
Estimated values of π1 ranged from 0.54 to 0.90 (Fig. 2B). For every pair of tissues, we 
observed a high level of sharing of eQTLs, and this pairwise sharing of eQTL among tissues 
roughly mirrored the tissue gene expression correlations (fig. S12).
To assess patterns of sharing beyond tissue pairs, we applied two Bayesian methods that 
assess, for each SNP-gene pair, the evidence for each of the 512 (29) possible null/
alternative eQTL configurations. The first method (24) is “gene-based” and assumes a single 
causal eQTL per gene. We extended the model to (i) support the fact that not all tissues were 
sampled across all GTEx donors; (ii) calculate a gene-level FDR without requiring 
permutations (27); and (iii) include a fine mapping approach across multiple tissues (28). 
We also used a “SNP-based” approach (25), which assesses association of each SNP-gene 
pair separately, working directly with the z-statistics for each SNP-gene pair within each 
tissue [see also (29)]. We summarized the estimates of tissue specificity using marginal 
posterior probabilities for the number of tissues in which a randomly selected gene (gene-
based model) or SNP-gene pair (SNP-based model) is active (Fig. 2C). Both approaches 
show a U-shaped pattern, with high tissue specificity (activity in a single tissue) or tissue 
ubiquity (activity in all nine tissues) more common than profiles involving only a few 
tissues, despite many more possible combinatorial patterns for intermediate specificity. 
Notably, both methods indicate that more than 50% of all detected eQTLs are common to all 
nine tissues. Reassuringly, both Bayesian methods produce pairwise tissue sharing 
probabilities that show agreement with the non–model-based analysis (fig. S13). Figure S14 
illustrates the value of the multitissue analysis for an example in which the tissue specificity 
of an eQTL supports NDRG4 as a candidate to influence QT interval in the heart (30). 
Despite superficial similarity between patterns of tissue-tissue gene expression and eQTL 
sharing, extensive comparisons of eQTL evidence to expression levels indicate that the 
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tissue-specific patterns are only modestly correlated with average tissue expression levels 
(fig. S15).
We also examined effect size estimates for eQTLs that are shared between tissues. The vast 
majority of shared eQTLs show consistent effect directions in different tissues. However, 
some SNPs showed apparent opposite effect directions in different tissues (fig. S16). A 
number of examples that we investigated using multi-SNP multitissue analyses (28) 
appeared to be due to pairs of SNPs, in LD with one another, that were separate eQTLs in 
different tissues (fig. S17) rather than being a single eQTL with opposite effects.
Beyond the biological interest of eQTL sharing among tissues, the availability of multiple 
tissues can also increase the power to detect eQTLs active in multiple tissues by combining 
information across tissues (24). To investigate, we conducted a permutation analysis by 
holding the expression data fixed and permuting the genotypes. In this manner, we identified 
the significant eGenes per tissue (as in the single-tissue analysis above, but for a smaller 
window near the TSS), or jointly for any combination of tissues by considering the 
minimum P value across tissues under each permutation. With this approach, the number of 
eGenes identified for individual tissues was similar to the single-tissue eQTL analysis (Fig. 
2A). Next, the minimum P value for each gene across all nine tissues was used to test for 
eQTL evidence, and subjected to gene-level false discovery control. A total of 7425 eGenes 
with FDR < 0.05 were identified, representing a factor of 3 increase relative to the maximum 
number of significant eGenes for any single tissue. The Bayesian models, which leverage 
the high proportion of tissue-common eQTLs, increase the power to detect eQTLs for an 
individual tissue by borrowing strength from the remaining tissues. Thus, of the original 
22,286 expressed genes, 10,030 showed a significant eQTL (FDR < 0.05) with the gene-
based Bayesian multitissue model (approximately 35% more than by joint permutation). 
Using the SNP-based Bayesian model, we selected four of the tissues with the largest 
sample sizes, and computed the marginal eQTL probability for each tissue alone after 
adding one to eight additional tissues in a fixed sequence. This resulted in a marked increase 
in the number of significant SNP-gene pairs (FDR < 0.05) (Fig. 2D). For downstream 
analyses using the multitissue results, a single SNP with highest posterior probability was 
chosen as representative across all tissues, recognizing that multiple causal SNPs would be 
difficult to resolve with the current sample size. Posterior probability profiles for both 
Bayesian models, as well as marginal posterior probabilities that an eQTL is active in each 
tissue, based on summing the probabilities across all configurations, are available for these 
genes (http://gtexportal.org).
Allele-specific expression analysis
To complement eQTL analysis, we used allele-specific expression (ASE) of genes to 
indirectly estimate the overall effect of cis-regulatory variants on the expression of nearby 
genes. Individuals that are heterozygous for a cis-regulatory variant may differentially 
express each of the two alleles of the affected gene. In these cases, assuming no other causes 
for allele-specific expression, imbalanced allelic expression of a gene can be used to infer 
the effect of cis regulation on the gene even without necessarily identifying the specific 
regulatory variant(s). In addition to the subtle cis-regulatory effects described here, ASE of 
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premature stop variants is also informative of nonsense-mediated decay (31), and consistent 
monoallelic expression of specific genes can be used to detect epigenetic silencing by 
imprinting.
ASE can be estimated from the abundance of RNA-seq reads supporting each of the gene’s 
alleles, measured at heterozygous sites within the transcribed region. We identified a median 
of 6385 sites per sample (across all tissues and all individuals) that were both heterozygous 
for a transcript SNP in the imputed genotype data of the associated individual and well 
expressed in that sample (SNP covered by ≥ 30 RNA-seq reads) (fig. S18). Of these sites, a 
median of 390 sites per sample had significant ASE (binomial P < 0.005, or 144 sites with 
FDR 21%, after rigorous quality control of ASE sites and after downsampling to exactly 30 
reads at each site to ensure equal power to detect ASE) (Fig. 3A and table S8A) (14). To 
assess whether different tissues vary in terms of the overall effect of cis-regulatory variation 
in them, we estimated the proportion of those sites with significant ASE in each of the 
tissues (combining data from all individuals) (14) and found that the fraction of significant 
ASE sites varied widely across tissues, with a range of 1.7 to 3.7% (median 2.3%). Brain 
regions appeared depleted for allelic effects (2.0% ASE in brain versus 2.7% in other tissues 
combined; P < 2 × 10−16, Fisher’s exact test) (Fig. 3A), consistent with the hypothesis that 
brain-specific genes exhibit reduced genetic diversity (32). Our results generally support our 
eQTL findings; in thyroid, where we observed a high number of eQTLs (Fig. 2A), we also 
see an increased amount of ASE (Fig. 3B). Blood and LCLs have a higher proportion of 
allelic effects (3.6% versus 2.3% in others; P < 2 × 10−16, Fisher’s exact test) (Fig. 3B), 
suggesting nongenetic sources of monoallelic expression possibly due to the more clonal 
nature of these cells (33).
To compare between-sample and between-tissue sharing of ASE with the overall similarity 
of gene expression, we constructed two Spearman rank correlation matrices between all 
pairs of samples. In one, we correlated ASE ratios, capturing sharing of cis regulation; in the 
other, we correlated total coverage of the same sites, capturing similarity of overall gene 
expression levels, analyzing genes that are expressed in both tissues (both matrices used 
counts of reads covering heterozygous sites shared between the compared pair of samples) 
(14). The two matrices of tissue medians were highly correlated (Mantel test, r = 0.772, P < 
0.0001; fig. S19), indicating that tissues with similar gene expression profiles also have a 
higher degree of sharing of genetic regulatory effects.
Interestingly, when partitioning the full sample-level matrix into correlations between 
samples from different tissues of the same individual, the same tissue across individuals, or 
different individuals and different tissues (Fig. 3C), we found more complex relationships 
between total expression and allelic ratios. As expected, expression levels are determined by 
tissue, and samples cluster by tissue (75.6% of variance; Fig. 3E and table S8B). However, 
allelic ratios show the opposite pattern (Fig. 3D), with higher correlation among tissues 
within the same individual (17.9% of variance) than among individuals for the same tissue 
(8.6%). These results indicate that ASE is primarily determined by the common genome 
among different tissues of the same individual (34). This suggests that the two dimensions of 
gene expression variability, gene expression levels and allelic ratios, are largely defined by 
independent factors.
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ASE analysis can also be used as orthogonal confirmation of eQTL effects, on the basis of 
the expectation that individuals who are heterozygous for a cis-eQTL variant should 
manifest biased allelic ratios in the eQTL target gene. We performed this analysis at the 
genome-wide level across all the tissues in the GTEx data set, including the tissues with 
sample sizes that were too small for eQTL analysis. Examining the significant eQTLs 
identified by single-tissue analysis for the nine main tissues, we looked at their ASE effects 
separately in each of the 42 tissues, calculating the odds ratio of significant versus 
nonsignificant ASE for eQTL heterozygote versus homozygote individuals (e.g., for thyroid 
eQTLs we looked for ASE in all 42 tissues, then for blood eQTLs and so on) (figs. S20 and 
S21). In addition to replication of eQTL signals in the discovery tissue, we can estimate how 
relevant our eQTL findings from nine tissues are to a wide variety of other tissues 
(independent of sample size or allele frequency) and then assess which tissue is the best 
proxy for capturing regulatory effects in another tissues of interest.
We found that the overall tissue specificity of the eQTL sets varies. For example, eQTLs 
identified in skeletal muscle were less active in other tissues. Some tissues, such as brain, 
were not well captured by any of the nine eQTL sets here. ASE analysis also allows 
quantification of genome-wide tissue sharing of cis-regulatory signals without relying on 
eQTL discovery, but instead by measuring how often a site with a significant ASE signal in 
one tissue is significant in another tissue of the same individual. The proportion of shared 
ASE effects between tissue pairs within an individual varies between 36% and 58% (mean 
46%), with slightly increased sharing observed between closely related tissues (conditioning 
on each site being measurable in both of the tissues) (fig. S22A). This relatively high degree 
of sharing is consistent with the eQTL results described above. If we relax the constraint of 
requiring a gene to be expressed in both tissues, then the proportion of shared ASE effects is 
substantially lower (0.85 to 39%, mean 11%; fig. S22B). This finding represents the total 
probability of detecting a regulatory effect in another tissue, and highlights a high degree of 
apparent tissue specificity that derives from the fact that a gene expressed in one tissue is 
often simply not expressed in another. This is particularly pronounced in brain, where the 
large proportion of genes showing tissue-specific isoform expression in that organ (17) 
drives a lower degree of overall sharing. Whole blood and skeletal muscle are partial 
outliers, relative to other tissues, with lower sharing of eQTLs and lower average replication 
in other tissues (Fig. 2A, fig. S12, and figs. S20 to S22).
Although eQTL analysis and other association-based analyses are efficient for identifying 
common variants with phenotypic effects in populations, the genotype of those variants may 
not be a good indicator of the gene expression phenotype at an individual level. We 
investigated this using ASE analysis to estimate how consistent the allelic effect of single-
tissue eQTL variants are across individuals that share the same genotype for the best 
associated eQTL variant per gene. We tested a subset of 606 eQTLs that had high read 
coverage and a large number of samples for transcript heterozygous sites in the eQTL 
discovery tissue. We identified 53 eQTLs with significant replication of the eQTL signal in 
ASE, as inferred by higher allelic imbalance in eQTL heterozygotes than in homozygotes 
(linear regression P < 0.05 after Bonferroni correction; Fig. 4, A and B). Further, for 22 of 
the 53 eQTL genes, individuals show variability in their allelic ratios that cannot be 
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accounted for by the eQTL genotype or sampling error (Bonferroni corrected P < 0.05 from 
permutation of read counts; Fig. 4, C and D). These results highlight that common eQTLs do 
not explain all of the cis-regulatory effects in individuals and are inadequate predictors of 
allelic expression variance at the individual level. The higher variance in eQTL 
heterozygotes than in homozygotes (Mann-Whitney P = 2.13 × 10−7; Fig. 4B) suggests that 
part of this variance might originate from modification of the main eQTL effect by 
environmental or trans effects, or due to additional, independent regulatory variants (34).
Analysis of splicing QTLs
Beyond estimating overall levels of gene expression, RNA-seq data also allow for the 
quantification of expression levels of individual transcript isoforms, as well as components 
of these, such as exons, splice junctions, and untranslated regions. We refer to the 
quantitative variation of gene structure due to genetic variation as splicing QTLs (sQTLs) 
(Fig. 5A). To identify sQTLs, we used Altrans (35), a method that identifies SNPs that are 
associated with variation in the expression levels of exon junctions (sjQTLs; box S1) (14), 
and sQTLSeekeR (36), a method that identifies SNPs associated with the variation in the 
relative abundances of gene transcript isoforms (srQTLs; box S1) (14). Altrans identifies 
both novel and annotated splicing events, while sQTLSeekeR tests only annotated isoforms. 
Altrans, however, is restricted to changes in the usage of splice junctions, while 
sQTLSeekeR can in principle detect any variation in the relative abundance of transcript 
isoforms (fig. S23). Altrans was run using a ±1 Mb region around the TSS, while for 
sQTLseekeR, we tested within the body of the gene ±5 kb (14).
We detected an average of ~1900 genes with Altrans, and ~250 with sQTLseekeR, with at 
least one cis-sQTL per tissue (FDR = 0.05; table S9). The greater genomic window tested 
around the TSS for Altrans, and the capacity to detect novel splicing events, explains the 
much larger number of sQTLs detected by Altrans than by sQTLseekeR (about 70% of 
Altrans sQTLs correspond to novel events, and only about 10% map within 5 kb of 
annotated genes). Despite the difference, Altrans and sQTLseekeR show strong 
complementarity, detecting variants that are associated with very different types of 
alternative splicing events. Most of the splice events detected by Altrans (80%) are exon-
skipping events, while 60% of those detected by sQTLseekeR correspond to complex splice 
events, such as mutually exclusive exons (Fig. 5B and fig. S23). If we consider only sQTLs 
associated with exon-skipping events, the overlap in sQTLs identified by both methods is 
substantial (36% of sQTLseekeR are also found by Altrans, P = 0.004) (figs. S23 to S25). 
An example of an sQTL that we identified with potential biological relevance is shown in 
Fig. 5A (further examples are in fig. S26).
Significant sQTLs show a high degree of sharing among tissue pairs, with tissue-specific 
sQTLs accounting only for 7 to 21% of the total depending on the tissue (figs. S27 and S28). 
The highest degree of sharing is between heart left ventricle and whole blood, whereas the 
two tissues that share the fewest sQTLs are whole blood and Sun-exposed skin. In general, 
sQTLs identified in whole blood are shared at lower levels with other tissues, as was 
observed for eQTLs (Fig. 2A and fig. S12, A and B). Although we observe the same 
enrichment of sQTLs around the TSS as seen for eQTLs, the sQTLs that are shared across 
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multiple tissues tend to be closer to the TSS than those that are tissue-specific (fig. S28). On 
average, 20% of sQTLs associated with changes in exon junction abundance by Altrans 
were also predicted to be eQTLs (π1 = 0.20, π1 = 0.14 to 0.27; table S10). An even larger 
fraction (48%) of sQTLs detected by sQTLseekeR associated with changes in relative 
abundances of gene transcript isoforms, were identified as eQTLs (π1 = 0.48, π1 = 0.13 to 
0.70; table S10). This enrichment of eQTLs among sQTLs is larger than expected at FDR < 
0.05, but a substantial fraction of sQTLs are unique and not detected by standard eQTL 
analysis.
Functional annotation of eQTLs in noncoding regions
Genetic variants affecting gene expression and splicing patterns have been shown to fall 
within regulatory elements, providing a potential molecular basis for their effects (37–39). 
To assess whether the eQTLs discovered across the nine tissues were enriched in regulatory 
regions, we used a set of regulatory annotations from the ENCODE project (10) and the 
Epigenomics Roadmap project (40), including regulator-bound locations, DNase I 
hypersensitivity sites, and maps of histone modifications for proximal and distal regulatory 
regions (14). For each tissue, we chose the top significant SNP per gene from the single-
tissue eQTL analysis (14,431 eQTL SNPs). Discarding SNPs that were within annotated 
genes resulted in 4085 intergenic eQTL SNPs, which were compared to our regulatory 
annotations (14). Intergenic eQTL SNPs were enriched for transcription factor-bound sites, 
open chromatin, promoters, and enhancers (P = 4.3 × 10−18, 2.9 × 10−8, 1.7 × 10−19, and 
0.003, respectively) relative to the density of these features within a 2.5-kb window of the 
tested eQTLs (fig. S29 and table S11). This enrichment was even more pronounced in a 
subset of 91 unambiguous intergenic eQTL SNPs (fig. S29). In contrast, we found sQTLs to 
be enriched within annotated splice junctions relative to other functional regions (Fig. 5C).
We also asked whether the specific SNP-gene links (“genetic links”) predicted by our eQTL 
analysis were supported by enhancer-gene links based on functional correlation (“functional 
links”) (14). We found that open chromatin regions containing an eQTL SNP show higher 
correlation to the corresponding gene, relative to open chromatin regions without an eQTL 
at similar distances and linked to genes also containing an independent eQTL (r = 0.037 
versus 0.030, paired Mann-Whitney two-sided P = 4.3 × 10−11, SE = 0.00114, n = 32,168 
eQTL-SNP pairs).
This demonstrates the value of eQTL information to establish functional links between 
regulatory elements and genes in the genome, an analysis that will increase in power as 
additional tissues and subjects are added to the data set.
Gene network inference within tissues using cross-individual expression 
variation
To provide a view of coordinated gene regulation arising from both cis and trans genetic 
effects and nongenetic sources, we inferred gene-gene coexpression networks within tissues. 
Studying each of the nine tissues in isolation and examining variation of gene expression 
across individuals, we linked pairs of genes that show correlated expression (top 1% of pairs 
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by Pearson correlation) (14), revealing similar patterns of coexpression across tissue pairs 
(Fig. 6A). The median π1 statistic (fraction of true positive results) (26), estimating the total 
fraction of coexpressed gene pairs identified in one tissue that are replicated in a second 
tissue, is 0.44, ranging from 0.30 to 0.58 (Fig. 6A). Furthermore, the specific tissue pairs 
with higher overlap of coexpressed genes also have a greater overlap of cis-eQTLs than 
other tissue pairs, indicating a similar pattern of tissue relatedness underlying both results (P 
< 0.05 for correlation between similarity matrices of Figs. 2B and 6A). Thus, although 
coexpression networks primarily capture non-cis mechanisms, including trans regulation and 
environmental factors, the overall level of sharing and the specific patterns of tissue 
relatedness agree with the patterns observed from cis-eQTLs, which suggests that regulatory 
mechanisms beyond cis effects may be shared across tissues.
We also used a weighted gene coexpression network analysis (WGCNA) approach (41) to 
construct coexpression networks and extract gene modules for each tissue (Fig. 6B). The 
clustering of coexpressed genes into modules allows us to identify active biological 
processes across tissues (Fig. 6C). Modules enriched for common Gene Ontology (GO) 
biological processes were observed in all nine tissues (e.g., cell cycle, protein transport), 
while other biological processes were only seen in specific tissues (e.g., fatty-acyl-CoA 
metabolic process enrichment seen only in adipose, Benjamini-Hochberg corrected P = 2.6 
× 10−7) (14). In addition to functional annotation, the identified coexpression networks also 
enabled us to search for potential transcriptional regulators of these modules (Fig. 6D). We 
found enrichment of transcription factor binding in promoter regions of genes in the same 
module using ENCODE chromatin immunoprecipitation (ChIP)–seq data (42), suggesting 
that some modules could be regulated by a large number of transcription factors (fig. S30A). 
Finally, we compared coexpression modules learned in each tissue individually to those 
learned in other tissues, based on common gene membership and correlation of first 
principal components of expression variation across individuals (fig. S30B). Many modules 
showed correlation between principal components to other modules across tissues but lacked 
common genes, demonstrating that similarity in patterns of variation is sometimes only 
visible at the module level.
Gene network inference within individuals using cross-tissue expression 
variation
The availability of multiple tissues per individual further allowed us to define modules of 
co-regulated genes within each individual, by correlating gene expression across tissues for 
the same individual (14). Merging modules across individuals produced 117 modules (fig. 
S6E), containing between 25 and 414 genes. Each of these modules corresponds to a 
multitissue expression pattern for a gene, enabling us to study changes in the regulatory 
program of genes that affect multiple tissues at a time.
We used these modules to identify instances of coordinated variation in multitissue 
expression patterns across individuals. For each gene, we estimated the proximity of each 
individual’s expression pattern to the median expression pattern of each module, 
corresponding to a “module membership score” (Fig. 6F and fig. S31A). We then calculated 
a module membership score for each individual (Fig. 6G) (14). Cases where depletion in 
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membership of one module was accompanied by a corresponding increase in membership of 
a different module are called “module switching events.” The majority of genes showed 
conserved multitissue gene expression patterns among individuals, remaining in the same 
module or switching between modules with similar expression patterns (correlation distance 
< 0.5). However, we identified 3965 genes (21%) that show switching between dissimilar 
modules (correlation distance > 0.5), which may have important biological consequences 
(fig. S31B). Using module membership scores as a quantitative trait, we searched for 
neighboring SNPs that are correlated with these module membership scores (Fig. 6H), 
which we call module-switching QTLs (modQTLs). Searching a window of 1Mbp around 
each gene in cis, we found a total of 2102 modQTLs associated with statistically significant 
switching (FDR < 0.05) between dissimilar gene modules (correlation distance > 0.5), 
suggesting that genetic variation for those genes leads to changes in multitissue regulatory 
programs. For example, the ZFP57 gene shows three distinct patterns of multitissue 
expression across individuals, and three nearby SNPs are associated with these changes, 
suggesting a genetic basis for these multitissue differences (Fig. 6H).
We compared the 2102 modQTLs with eQTLs discovered by both the single-tissue and 
multitissue eQTL analyses. At all correlation levels of stringency, the modQTLs capture 
53% of tissue-specific eQTLs (calculated as the percentage of lead SNPs in LD r2 > 0.8 with 
lead modQTLs) and 60% of multitissue eQTLs, and these two together account for only 
42% of modQTL SNPs. Hence, 58% of modQTLs are not discovered by other methods, 
which suggests that the approach has the potential to reveal novel genetic effects on the 
modulation of genes across tissues (fig. S31C).
Personal transcriptomics and implications for human disease
The in-depth analysis of multitissue transcriptomes enables both an understanding of the 
population-level properties of the transcriptome as well as individual level properties 
inferred from analyses of single transcriptomes or the transcriptomes of multiple tissues 
from a single individual. As is the case for personalized genomics, this individual-level 
transcriptome analysis is likely to become a crucial addition to the personalized assessment 
of an individual’s biology and likely disease status.
Impact of individual gene-disrupting variants on splicing and expression
Assessing the functional impact of DNA sequence variants identified in whole-genome and 
exome sequencing studies remains a major challenge. Variants predicted to result in the 
truncation of proteins (splice, stop-gain SNVs, or frame-shift indels) may have large effects 
on biochemical function, but are also highly enriched for annotation artifacts (43). Errors in 
predicting the true functional impact of these and other variants can substantially reduce 
discovery power in common complex diseases and, more important, can affect disease 
diagnosis in clinical settings (44).
The GTEx multitissue expression data provide an opportunity to assess the real impact of 
protein-truncating variants (PTVs) on the human transcriptome [see also (31)]. We 
combined exome sequencing and RNA-seq data from 173 GTEx individuals to assess the 
global properties of predicted high-confidence PTVs (14). PTVs are enriched in 
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alternatively spliced exons, with just 38.4% of high-confidence PTVs having annotation 
support across all reported transcripts (Fig. 7A), and only 51 to 55% supported by the major 
transcript of at least one tissue (for all tissues with at least 10 samples). These numbers 
highlight the need for careful transcript-specific assessment of functional annotation for all 
classes of variation. Furthermore, if we require that a fixed percentage of the dominant 
isoforms across all sequenced tissues support this annotation, we find that the percentage of 
predicted PTVs with annotation support of PTV decreases as we increase the threshold for 
the proportion of tissues with major transcript isoform support for PTV prediction (Fig. 7B). 
This highlights the need for empirically derived reference transcript sets across a broad array 
of tissues to enhance clinical interpretation for personal genome sequencing and disease 
studies. An example with clinical ramifications is shown in fig. S32.
GWAS and eQTLs
The ultimate goal of the GTEx project is to provide a framework for biological 
interpretation of disease-related variants. To evaluate the relevance of the discovered eQTLs 
in disease mapping studies, we tested the eQTLs identified in each tissue for association 
with disease using the Wellcome Trust Case Control Consortium (WTCCC) studies of seven 
complex disorders (45) (see Fig. 8A). Using eQTLs identified in whole blood, we found an 
enrichment for top associations with autoimmune diseases (shown as a leftward shift from 
the null distribution in the Q-Q plot in Fig. 8A), for Crohn’s disease, rheumatoid arthritis, 
and type 1 diabetes among eQTLs (P < 2.2 × 10−16 for each disease), consistent with the 
utility of blood and lymphoblastoid cell lines (LCLs) in trait mapping for autoimmune 
disorders (46, 47). In contrast to the autoimmune disorders, we found no enrichment for 
association (no shift in P value distribution) with bipolar disorder or type 2 diabetes among 
the blood eQTLs (P > 0.05) (Fig. 8A). This tissue specificity of autoimmune enrichment 
results suggests they are not due to the confounding effects that result from similar 
underlying genomic properties between eQTL and disease association regions. More 
generally, we observed trait-specific levels of enrichment for the WTCCC disease traits 
among the nine different single-tissue eQTL sets.
Remarkably, the use of eQTLs increased power to detect associations with hypertension 
(Fig. 8B). In particular, eQTLs in subcutaneous adipose were significantly enriched for 
multiple associations with hypertension relative to muscle, lung, thyroid, skin, heart, and 
tibial artery (P < 0.05, Kolmogorov-Smirnov test) (Fig. 8B). This is particularly noteworthy 
because the WTCCC GWAS of this disease did not yield any genome-wide significant 
associations, which suggests that larger sample sizes were required to identify highly 
significant SNP associations in the absence of functional data. Because the majority of 
GWAS-identified variants (~95%) lie in noncoding regions of the genome, we determined 
which genome-wide significant trait associations (P < 5 × 10−8) reported to date are in LD 
with at least one GTEx-identified eQTL. We merged NCBI’s Phenotype-Genotype 
Integrator (PheGenI) (48) and the NHGRI GWAS catalog (49), yielding 10,129 genome-
wide significant SNP associations with nearly 630 distinct complex traits. In total, 5195 
“independent” SNPs were identified after LD pruning at r2 ≥ 0.8 and counting SNPs only 
once (14). Of these, 308 (~6%) are in strong LD(r2 ≥ 0.8), with a “best eQTL per gene” (at 
FDR < 0.05) from either the single-tissue or multitissue eQTL discovery analysis (table S12) 
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in at least one of the nine tissues tested. For two-thirds of these cases (211 SNPs), no 
putative deleterious coding variants (nonsynonymous or splice variants) in the target gene 
product lie in LD (r2 ≥ 0.8) with the GWAS SNP; this finding suggests that regulatory 
effects may underlie the causal mechanism, although additional work is needed to prove 
causality. GWAS SNPs in LD with an eQTL show a factor of 2 higher representation in 
coding regions relative to all GWAS SNPs (11% versus 4.6%; table S13). Notably, about 
one-third of the eQTLs in LD with GWAS SNPs were detected only with methods that 
leverage the multitissue nature of GTEx data. Increasing both sample sizes and the range of 
tissues will likely increase the number of detected GWAS-eQTL loci.
Annotating a GWAS SNP with an eQTL can help to highlight candidate causal genes within 
a locus (i.e., the eQTL target gene). We found that proximity-based and eQTL-based gene 
assignments for GWAS SNPs were often discordant (47). A surprising proportion of trait-
associated SNPs in LD (r2 ≥ 0.80) with a GTEx eQTL showed disagreement between the 
strongest eQTL-derived target gene and the genes that were physically proximal to the 
GWAS SNP (table S14). Of 190 GWAS loci (P < 5 × 10−8) where the lead SNP is an eQTL 
from the single-tissue analysis (FDR < 0.05) with only a single target gene, in 65 cases 
(~34%) this eQTL target gene differs from any of the genes that were closest to the SNPs in 
LD. These results were also observed when we restricted the target genes to protein-coding 
genes, when we pruned the GWAS SNPs for each trait examined (r2 ≥ 0.80), and when we 
used the eQTLs identified from the multitissue joint eQTL analysis.
In addition to prioritizing causal genes in GWAS loci, an eQTL catalog from multiple 
human tissues can highlight the relevant tissue(s) of action, evaluate the tissue specificity of 
GWAS loci, and characterize pleiotropic associations. We demonstrate the value of 
multitissue data to explore and resolve these issues for the GWAS intronic SNP, rs633185, 
located in ARHGAP42 (Fig. 9). This GWAS SNP is in high LD (r2 = 0.93) with the best cis-
eQTL (rs604723) targeting ARHGAP42, and the best cis-eQTL for a neighboring gene, 
TMEM133 in tibial artery. Evaluating eQTL significance in all nine tissues shows that 
although the eQTL’s significance is indeed strongest in tibial artery, several other tissues 
may merit consideration in exploring the causal function of this locus, such as subcutaneous 
adipose and skin (Fig. 9, B and C, and fig. S33). This supports the need to explore the 
genetic basis of disease in the fuller context of a wide range of human tissues. The GTEx 
eQTLs may also be useful in highlighting the role of noncoding genes in disease risk and 
other complex traits (fig. S34). We found that ~13% of candidate genes proposed by GTEx 
eQTLs, and in LD to genome-wide significant GWAS SNPs, are noncoding genes (table 
S15).
Conclusions
We have described a large in-depth data set of multitissue human gene expression. We 
assessed the variability of the transcriptome among individuals in a large number of tissues 
at a resolution that provides unique insights in to the diversity and regulation of gene 
expression among tissues. This analysis provides a unified view of genetic effects on gene 
expression across a broad range of tissue types, most of which have not been studied for 
eQTLs previously. We look forward to scaling up the resource to create a data set that will 
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transform our understanding of how genetic variability influences different tissues and 
biological systems and ultimately complex diseases.
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Fig. 1. Sample clustering based on gene expression and exon splicing profiles
(A) Clustering performed on the basis of gene expression values for all genes from Gencode 
v12 annotation. Tissue type is the primary driver of expression differences, with the 
nonsolid tissues (blood and LCL cell lines) clustering separately from solid tissues. 
Hierarchical clustering was performed using as distance = 1 – Pearson correlation, and 
average method. (B) Sample clustering based on the “percent spliced in” (PSI) values for 
exons across samples. Tissue differentiation is less clearly a driver, and brain is now the 
main outgroup, driven largely by a cluster comprised of cerebellum and cortex samples.
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Fig. 2. Number and sharing of significant ciseQTLs per tissue
(A) Numbers of significant cis-eQTL genes (eGenes) per tissue according to single-tissue 
analysis. For each gene, the minimum nominal P value was used as the test statistic and an 
empirical P value was computed to correct for number of tests per gene, based on either 
permutation analysis of genotype sample labels applied to the full set of samples per tissue 
(◆) or Bonferroni correction, used for downsampling (line) to reduce computational burden 
(14). In the range of sample sizes tested, the number of identified eGenes increases linearly 
with sample size. (B) Dendrogram and heat map of pairwise eQTL sharing using the method 
of Nica et al. (22). Values are not symmetrical, since each entry in row i and column j is an 
estimate of π1 = Pr(eQTL in tissue i given an eQTL in tissue j). Blood has the lowest levels 
of eQTL sharing with other tissues while adipose shows higher levels of sharing. (C) 
Activity probabilities for both multitissue modeling approaches, applied to all nine tissues, 
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indicate that the most likely configurations are for eQTLs that are active in only a few 
tissues or in many tissues. (D) For eQTLs in each tissue considered separately, analyzing 
multiple tissues jointly increases the number of discovered eQTL associations (FDR < 0.05), 
as assessed by the SNP-based multitissue model.
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Fig. 3. Quantification of regulatory diversity by ASE
(A) Proportion of sites with significant ASE (P < 0.005) in each tissue (colored and labeled 
as in Table 1), with binomial confidence intervals. (B) Proportion of significant ASE sites 
for the nine tissues with eQTL data as a function of the proportion of eQTLs after regressing 
out the log of sample size. (C) Partitioning variation in allelic and total gene expression 
within and between individuals and tissues. We calculated pairwise Spearman rank 
correlations between all the samples using two metrics [(D) and (E)]. (D) Allelic ratios over 
sites (sampled to 30 reads each), which captures similarity in allelic effects that are a proxy 
for cis-regulatory variation. (E) Total read counts over the same sites, which captures 
similarity in total gene expression levels. The plots show the distributions of pairwise 
correlations for sample pairs that are from (1) different tissues and different individual, (2) 
different tissues within an individual, or (3) same tissues in different individuals. Gene 
expression levels are highly correlated within the same tissue (E3) (see Fig. 1A). However, 
allelic ratios show highest correlation among different tissues of the same individual that 
share the same genome (D2).
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Fig. 4. Cis-regulatory effects in individuals that are not explained by detected eQTLs
(A) An eQTL showing individual homozygous (AA) for the eQTL SNP (left panel) or 
heterozygous (AG) (right panel). ASE is measured at the TC SNP. (B) An example of 
replication of an eQTL signal in ASE analysis in the NDRG4 gene, with eQTL 
heterozygotes showing higher ASE in the eQTL target gene than eQTL homozygotes (only a 
subset of individuals shown; linear regression P = 5.69 × 10−6). The error bars are from a 
binomial test for the allelic ratio. (C) For each eQTL gene where the eQTL signal was 
replicated in ASE (linear regression P < 0.05 after Bonferroni correction), the eQTL 
heterozygotes show higher variance in allelic ratio (Mann-Whitney P = 2.13 × 10−7). (D) 
Permuted P value for the variance between individuals, which is higher than expected in 
22/53 genes (9 genes in homozygotes, 20 in heterozygotes).
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Fig. 5. Splicing QTLs
(A) A splicing QTL that affects the relative usage of alternative splice isoforms for the 
tRNA methyltransferase 1 homolog gene (TRMT1). TRMT1 has three annotated isoforms, 
only two of which are abundant in skeletal muscle. The relative abundance of the two 
isoforms differs by genotype (number of individuals below each genotype), with 
heterozygotes showing an intermediate behavior. This SNP has not been detected as an 
eQTL. The right panel shows the exonic structure of the transcripts along with the location 
of the sQTL SNP (dotted line). (B) The relative proportions of the different types of splicing 
events detected by the two methods over the nine tested tissues (fig. S23). (C) Functional 
enrichment of sQTLs from Altrans and sQTLseekeR. For the top-ranked SNPs associated 
with a given splicing event, we computed the relative frequency with which they map to 
different biologically determined ENCODE functional domains.
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Fig. 6. Coexpression networks within tissues and individuals
(A) Similarity of coexpression networks discovered in each tissue separately (rows) and 
replicated across all other tissues (columns), on the basis of the correlation in gene-pair 
expression levels across all individuals for a given tissue, as quantified by the π1 statistic. 
The tissues in this heat map are ordered as in Fig. 2B. (B) Coexpression modules learned 
within adipose tissue on the basis of weighted gene coexpression network analysis 
(WGCNA). The heat map shows the similarity in gene expression patterns (across 
individuals) for each pair of genes expressed within adipose tissue (red = high correlation, 
blue = low correlation). Non-gray colors highlight separate modules. (C and D) Genes in the 
same adipose coexpressed module [(C), rows] show enrichment for similar gene ontology 
(GO) categories (columns) and are co-bound by the same transcription factors (TF) [(D), 
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columns] in their transcription start site (blue = Benjamini-Hochberg corrected P < 0.01). 
Dendrogram (top) denotes TF-to-TF similarity in module targeting. (E) Average expression 
level (red = high, blue = low) in each tissue (rows) across 117 expression modules 
(columns). Modules highlighted include Mod6, showing highest expression in whole blood 
and cortex; Mod95, showing highest expression in noncortex brain; and Mod101, showing 
brainwide expression. (F) Expression pattern of 175 individuals (columns) across 45 tissues 
(rows) for the ZFP57 gene encoding a KRAB domain transcription factor. Colored entries 
denote expression levels (heat map). White entries denote missing expression measurements 
for an individual in a given tissue. (G) Probability of membership of each individual 
(columns) in each expression module (rows) for the three most significant modules 
[highlighted in (E)]. (H) Genotype of the three top modQTL SNPs (rows) across individuals 
(columns) shows correlation with module membership probability.
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Fig. 7. Integration of transcriptome data improves annotation of putative protein truncating 
variants (PTVs)
(A) The majority of annotated PTV variants are partial PTV, meaning that only a fraction of 
the RNA-seq transcripts support PTV annotation. (B) For all the predicted PTV variants, we 
ask what percentage of variants maintain a PTV annotation if we require that a fixed 
percentage of the dominant isoforms across all sequenced tissues support a PTV prediction; 
70% of PTV variants are relevant if the threshold is 10%, whereas only 40% of PTV 
variants are relevant if the threshold is 100%.
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Fig. 8. Tissue-dependent GWAS eQTL enrichment Q-Q plots
(A) eQTLs are enriched for trait associations with an important class of complex diseases. 
eQTLs discovered in whole blood (plotted in red) show significant enrichment for SNPs 
associated with autoimmune disorders from the WTCCC study (type 1 diabetes, Crohn’s 
disease, and rheumatoid arthritis) relative to null expectation (shown in gray) defined by 
non-eQTLs. (B) Enrichment of eQTLs for disease associations is tissue-dependent. Single-
tissue eQTL annotation can be used to increase power to detect associations with 
hypertension, a disease for which the WTCCC study failed to yield significant associations. 
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Notably, eQTLs discovered in adipose are enriched relative to muscle, lung, thyroid, skin, 
heart, and tibial artery (P < 0.05, Kolmogorov-Smirnov test) for known SNP associations 
with the hypertension.
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Fig. 9. A blood pressure-associated SNP is a significant eQTL in tibial artery, for ARHGAP42 
and TMEM133
(A) The GWAS SNP, rs633185 in the intron of ARHGAP42, is associated with systolic 
blood pressure (P = 1.2 × 10−17) and diastolic blood pressure (P = 2 × 10−15). This GWAS 
SNP is in tight LD (r2 = 0.93) with the most significant eQTL for ARHGAP42 in tibial 
artery, rs604723 (P = 1 × 10−8), and is the most significant eQTL for TMEM133 in tibial 
artery (P = 2.7 × 10−8). Tibial artery was the only significant tissue at FDR < 0.05 according 
to the single-tissue eQTL discovery method. (B) Average posterior probability of the most 
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significant cis-eQTL, rs607562 for ARHGAP42 at FDR < 0.05 from the multitissue eQTL 
methods. (C) Similar plot for TMEM133. The most significant cis-eQTL for TMEM133 
from the multitissue methods at FDR < 0.05 is the GWAS SNP, rs633185, in tibial artery.
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Characteristics of the 1641 RNA-sequenced samples included in the pilot data freeze. The second and third 
columns show the tissue abbreviation and color assigned to each tissue (used throughout). The nine tissues 
prioritized for sequencing are indicated by red stars. Boxes highlight two regions of the brain that were 
sampled in duplicate. A region each from the cerebellum and cortex (BRNCHA and BRNCTXA) was sampled 
on site during initial tissue collection, and again after the brain was received by the brain bank (BRNCHB and 














BRNCTXB). Cell lines included are an EBV-transformed lymphoblastoid cell line from blood (LCL) and a 
cultured primary fibroblast cell line from fresh skin (FIBRBLS). RIN, RNA integrity number.
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